In today’s briefing:
- Cochlear Limited: Initiation of Coverage- Can Cutting-Edge Innovation & R&D Fuel the Next Growth Surge?
- Next Science Asset Sale to Demetra Holdings: Potential 13% Upside with Capital Return and Strategic Acquisition
- Northern Star Resources: Initiation of Coverage- Why Mining Stabilization at Super Pit Could Be a Game-Changer!
- Mesoblast (MSB AU): Ryoncil Starts on a High Note- A Step Toward Profitable Growth
- Pro Medicus: Initiation of Coverage- Breaking Barriers in U.S. Imaging with Next-Gen Expansion Strategy!
- Santos Limited: Initiation of Coverage- Power Moves in Contracts, Decommissioning, & Growth!
Cochlear Limited: Initiation of Coverage- Can Cutting-Edge Innovation & R&D Fuel the Next Growth Surge?
- Cochlear Limited recently announced its half-year results for fiscal year 2025.
- In its earnings call, the company disclosed a mixed performance across its business segments.
- On the positive side, the company reported a strong 13% growth in Cochlear implant revenue and an even stronger 22% growth in Acoustics revenue, leading to an overall net sales increase of 6% in constant currency.
Next Science Asset Sale to Demetra Holdings: Potential 13% Upside with Capital Return and Strategic Acquisition
- Next Science plans to distribute net proceeds of US$30m from asset sale to shareholders, equating to A$0.158/share.
- The asset sale requires shareholder approval, with major stakeholders like the Walker family likely supporting the transaction.
- Uncertainties include FDA compliance issues, tax treatment of distribution, and potential changes in net proceeds estimate.
Northern Star Resources: Initiation of Coverage- Why Mining Stabilization at Super Pit Could Be a Game-Changer!
- Northern Star Resources Ltd’s March 2025 quarterly results showcased a strong financial and operational performance, despite facing some operational challenges.
- The company generated robust net mine cash flow of $295 million, with positive contributions from all production centers.
- The gold price, exceeding AUD 5,000 per ounce, aided this financial strength, alongside the company’s low-risk mining jurisdictions in Western Australia and Alaska.
Mesoblast (MSB AU): Ryoncil Starts on a High Note- A Step Toward Profitable Growth
- Mesoblast Ltd (MSB AU) reported $13.2M revenue from Ryoncil since its launch on March 28 through June 30. With full treatment cost of $1.55M, Ryoncil pricing has been reasonably set.
- With mandatory CMS coverage becoming effective on July 1 in all U.S. states and Mesoblast completing onboarding of the remaining major U.S. transplant centers, Ryoncil revenue is expected to accelerate.
- As of June 30, 2025, Mesoblast had cash balance of $162M. Considering cash burn of $16.6M for the latest quarter, the company has an estimated funding available for ~10 quarters.
Pro Medicus: Initiation of Coverage- Breaking Barriers in U.S. Imaging with Next-Gen Expansion Strategy!
- Pro Medicus Limited, a healthcare IT company specializing in enterprise imaging, reported a record first half of the fiscal year in both financial performance and strategic milestones.
- The company’s revenue increased by 31.1%, with profit after tax soaring by 42.7%, reflecting robust financial health.
- The earnings before interest and taxes (EBIT) margin grew to 71.9%, underscoring the company’s profitability.
Santos Limited: Initiation of Coverage- Power Moves in Contracts, Decommissioning, & Growth!
- Santos Limited reported its 2024 full-year financial and operational results, presenting a detailed picture of the company’s current status, achievements, and challenges.
- The company highlighted a strong financial performance supported by disciplined cost controls, robust revenues, and significant strategic projects either completed or progressing as scheduled.
- On the positive side, Santos reported sales revenue of $5.4 billion, which translated into $3.7 billion in EBITDAX and $1.2 billion in profit after tax.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
